Special Issue

DNA Damage and Radiotherapy

Message from the Guest Editor

Radiotherapy (RT) is one of the most common and effective treatment strategies for cancer, which is effective for not only localized but also metastasis tumors. During RT, exposure of cells to ionizing radiation (IR) induces DNA double-strand breaks (DSBs), which are a major cause for lethal damage to the DNA of cancer cells, as well as being responsible for the induction of side effects. The risks posed by DSBs to the genome of higher eukaryotes are mitigated by a network of signaling pathways collectively termed the DNA damage response (DDR). DDR detects DSBs and coordinates a wide spectrum of cellular responses, including checkpoint activation and DSB repair. DDR signaling factors targeting to develop strategies for the better targeting of tumors, while the protection of normal tissues has become a subject of intensive research, such as the utilization and characterization of new radiation modality, the development and investigation of novel inhibitors of individual DSB repair pathways, etc. We, therefore, invite authors to submit original and review articles on these topics.

- radiotherapy
- normal tissue protection
- DNA damage response (DDR)
- radiation modality

Guest Editor

Dr. Fanghua Li

Department of Particle Therapy, University Hospital Essen, West German Proton Therapy Centre Essen (WPE), West German Cancer Center (WTZ), German Cancer Consortium (DKTK), 45147 Essen, Germany

Deadline for manuscript submissions

closed (30 September 2023)

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/si/171712

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/journal/biomedicines

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).